Refine
Has Fulltext
- yes (19)
Is part of the Bibliography
- yes (19)
Document Type
- Journal article (19)
Language
- English (19)
Keywords
- angiogenesis (3)
- biomarker (3)
- prostate cancer (3)
- tumor microenvironment (3)
- cancer (2)
- kidney cancer (2)
- machine learning (2)
- metastasis (2)
- renal cell carcinoma (2)
- 68Ga-PSMA ligand PET/CT (1)
- COVID-19 (1)
- Cancer Cell (1)
- MTB (1)
- PCa (1)
- PET/CT (1)
- PSMA (1)
- PSMA-TV (1)
- RCC (1)
- SARS-CoV-2 (1)
- SOAT1 (1)
- SUV (1)
- Sunitinib (1)
- TKI (1)
- Tyrosine kinase inhibition (1)
- UMAP (1)
- agreement (1)
- androgen deprivation therapy (1)
- angiogenesis inhibitors (1)
- aplastic anemia (1)
- bone marrow failure (1)
- bone marrow immune-microenvironment (1)
- cancer care (1)
- cholesterol metabolism (1)
- clinical trials (1)
- comparability (1)
- cytopenia (1)
- detection rate (1)
- disorder of immunity (1)
- forecasting (1)
- hematopoietic stem cells (1)
- high-risk Prostate Cancer (1)
- high-risk prostate cancer (1)
- immune infiltration (1)
- immune-checkpoint inhibitor (1)
- immunotherapy (1)
- kidneys (1)
- mRNA (1)
- mTOR (1)
- metabolic tumour volume (MTV) (1)
- miR (1)
- miR-205 (1)
- miR-221-5p (1)
- miRNA (1)
- microRNA (1)
- microRNA-221 (1)
- migration (1)
- mitochondrial DNA (1)
- molecular subtypes (1)
- mtDNA (1)
- multiple myeloma (1)
- outcomes research (1)
- outreach (1)
- pan-RCC (1)
- patient access (1)
- precision medicine (1)
- precision oncology (1)
- predictive factors (1)
- prognosis (1)
- prognostic-biomarkers (1)
- proliferation (1)
- prostate adenocarcinoma (1)
- prostate-specific membrane antigen (PSMA) (1)
- radioligand therapy (1)
- real world data (1)
- recurrent prostate cancer (1)
- regression analysis (1)
- renal cancer (1)
- risk stratification (1)
- software (1)
- surgical and invasive medical procedures (1)
- surgical oncology (1)
- t-SNE (1)
- taxane (1)
- total lesion PSMA (1)
- transcriptome (1)
- transcriptomic analysis (1)
- tumor suppressor miRNA (1)
- venous infiltration (1)
- visual clustering (1)
Institute
- Urologische Klinik und Poliklinik (19)
- Comprehensive Cancer Center Mainfranken (10)
- Pathologisches Institut (6)
- Medizinische Klinik und Poliklinik II (5)
- Theodor-Boveri-Institut für Biowissenschaften (5)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (4)
- Klinik und Poliklinik für Nuklearmedizin (4)
- Center for Computational and Theoretical Biology (3)
- Medizinische Klinik und Poliklinik I (1)
Sonstige beteiligte Institutionen
Angiogenesis in metastatic castration-resistant prostate cancer (mCRPC) has been extensively investigated as a promising druggable biological process. Nonetheless, targeting angiogenesis has failed to impact overall survival (OS) in patients with mCRPC despite promising preclinical and early clinical data. This discrepancy prompted a literature review highlighting the tumor heterogeneity and biological context of Prostate Cancer (PCa). Narrowing the gap between the bench and bedside appears critical for developing novel therapeutic strategies. Searching clinicaltrials.gov for studies examining angiogenesis inhibition in patients with PCa resulted in n=20 trials with specific angiogenesis inhibitors currently recruiting (as of September 2021). Moreover, several other compounds with known anti-angiogenic properties – such as Metformin or Curcumin – are currently investigated. In general, angiogenesis-targeting strategies in PCa include biomarker-guided treatment stratification – as well as combinatorial approaches. Beyond established angiogenesis inhibitors, PCa therapies aiming at PSMA (Prostate Specific Membrane Antigen) hold the promise to have a substantial anti-angiogenic effect – due to PSMA´s abundant expression in tumor vasculature.